KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Castle Biosciences (CSTL) Enterprise Value: 2018-2025

Historic Enterprise Value for Castle Biosciences (CSTL) over the last 7 years, with Sep 2025 value amounting to $372.9 million.

  • Castle Biosciences' Enterprise Value fell 27.05% to $372.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$471.3 million, marking a year-over-year decrease of 104.19%. This contributed to the annual value of $453.3 million for FY2024, which is 34.25% up from last year.
  • According to the latest figures from Q3 2025, Castle Biosciences' Enterprise Value is $372.9 million, which was up 18.90% from $313.6 million recorded in Q2 2025.
  • In the past 5 years, Castle Biosciences' Enterprise Value registered a high of $1.5 billion during Q2 2021, and its lowest value of $140.7 million during Q2 2023.
  • Moreover, its 3-year median value for Enterprise Value was $341.3 million (2024), whereas its average is $339.1 million.
  • Its Enterprise Value has fluctuated over the past 5 years, first surged by 214.86% in 2021, then tumbled by 79.36% in 2022.
  • Castle Biosciences' Enterprise Value (Quarterly) stood at $755.0 million in 2021, then plummeted by 52.09% to $361.7 million in 2022, then declined by 6.65% to $337.6 million in 2023, then spiked by 34.25% to $453.3 million in 2024, then fell by 27.05% to $372.9 million in 2025.
  • Its Enterprise Value stands at $372.9 million for Q3 2025, versus $313.6 million for Q2 2025 and $295.7 million for Q1 2025.